BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 16506358)

  • 1. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease.
    Meier C; Meinhardt U; Greenfield JR; De Winter J; Nguyen TV; Dunstan CR; Seibel MJ
    Clin Lab; 2006; 52(1-2):1-10. PubMed ID: 16506358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
    Muñoz-Torres M; Reyes-García R; Mezquita-Raya P; Fernández-García D; Alonso G; Luna Jde D; Ruiz-Requena ME; Escobar-Jiménez F
    Maturitas; 2009 Nov; 64(3):188-92. PubMed ID: 19819089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
    Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
    J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cathepsin K predicts femoral neck bone mineral density change in nonosteoporotic peri- and early postmenopausal women.
    Prezelj J; Ostanek B; Logar DB; Marc J; Hawa G; Kocjan T
    Menopause; 2008; 15(2):369-73. PubMed ID: 17882010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
    Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
    Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis.
    Shaarawy M; Zaki S; Sheiba M; El-Minawi AM
    Clin Lab; 2003; 49(11-12):625-36. PubMed ID: 14651333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
    Tumminello FM; Flandina C; Crescimanno M; Leto G
    Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
    Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
    J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
    Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G
    Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
    Bonde M; Garnero P; Fledelius C; Qvist P; Delmas PD; Christiansen C
    J Bone Miner Res; 1997 Jul; 12(7):1028-34. PubMed ID: 9200001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between serum hsCRP concentration and biochemical bone turnover markers in healthy pre- and postmenopausal women.
    Kim BJ; Yu YM; Kim EN; Chung YE; Koh JM; Kim GS
    Clin Endocrinol (Oxf); 2007 Jul; 67(1):152-8. PubMed ID: 17466002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis.
    Verit FF; Geyikli I; Yazgan P; Celik A
    Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.
    Garnero P; Gineyts E; Arbault P; Christiansen C; Delmas PD
    J Bone Miner Res; 1995 Apr; 10(4):641-9. PubMed ID: 7610936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cathepsin K levels are not suitable to differentiate women with chronic bone disorders such as osteopenia and osteoporosis from healthy pre- and postmenopausal women.
    Adolf D; Wex T; Jahn O; Riebau C; Halangk W; Klose S; Westphal S; Amthauer H; Winckler S; Piatek S
    Maturitas; 2012 Feb; 71(2):169-72. PubMed ID: 22197348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paget's disease of bone: experience from a centre in southern India.
    Anjali ; Thomas N; Rajaratnam S; Shanthly N; Oommen R; Seshadri MS
    J Assoc Physicians India; 2006 Jul; 54():525-9. PubMed ID: 17089899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum bone specific alkaline phosphatase and urinary deoxypyridinoline in postmenopausal osteoporosis.
    Nawawi HM; Yazid TN; Ismail NM; Mohamad AR; Nirwana SI; Khalid BA
    Malays J Pathol; 2001 Dec; 23(2):79-88. PubMed ID: 12166596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased circulating Dickkopf-1 in Paget's disease of bone.
    Marshall MJ; Evans SF; Sharp CA; Powell DE; McCarthy HS; Davie MW
    Clin Biochem; 2009 Jul; 42(10-11):965-9. PubMed ID: 19389391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone alkaline phosphatase in Paget's disease.
    Deftos LJ; Wolfert RL; Hill CS
    Horm Metab Res; 1991 Nov; 23(11):559-61. PubMed ID: 1816067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.